Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in BRCA-mutated advanced cancers
NCT01078662Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, breast cancer, prostate cancer (PCa), pancreatic cancer (PC), sponsored by AstraZeneca. Started Feb 2010; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerbreast cancerprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01078662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01078662.